Goal of POSEIDON is to enable accurate, low-cost, accessible cancer screening for all Americans Program to deliver first-in-class synthetic-sensor based…
Goal of POSEIDON is to enable accurate, low-cost, accessible cancer screening for all Americans Program to deliver first-in-class synthetic-sensor based…
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology…
October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference…
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapiesROCKVILLE, Md., Oct. 06,…
SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage…
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with…
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:…
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to…
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company…